8-K Announcements
6Material company update
May 11, 2026·SEC
Material company update
Feb 24, 2026·SEC
Material company update
Jan 14, 2026·SEC
AbCellera Biologics Inc.(ABCL)Earnings, Financials & Key Ratios
ABCL•NASDAQ
Price updated Jun 19, 2026
AboutAbCellera Biologics Inc. develops antibody discovery platform. Its full-stack, artificial intelligence-powered antibody discovery platform searches and analyzes the database of natural immune systems to find antibodies that could be developed as drugs. As of December 31, 2021, the company had 156 discovery programs that are either completed, in progress, or under contract with 36 partners. AbCellera Biologics Inc. has a research collaboration and license agreement with Eli Lilly and Company. The company was incorporated in 2012 and is headquartered in Vancouver, Canada.Show more
- Revenue$75M+160.6%
- EBITDA-$188M+13.5%
- Net Income-$146M+10.1%
- EPS (Diluted)-0.49+10.9%
- Gross Margin61.64%-38.4%
- EBITDA Margin-250.61%+66.8%
- Operating Margin-288.98%+73.5%
- Net Margin-194.88%+65.5%
- ROE-13.33%+9.6%
ABCL Key Insights
AbCellera Biologics Inc. (ABCL) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Momentum leader: RS Rating 89 (top 11%)
- ✓Trading at only 1.4x book value
✗Weaknesses
- ✗Negative free cash flow
- ✗Sales declining 20.3% over 5 years
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
Get notified when ABCL posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
ABCL Price & Volume
AbCellera Biologics Inc. (ABCL) stock price & volume — 10-year historical chart
Loading chart...
ABCL Growth Metrics
AbCellera Biologics Inc. (ABCL) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-20.27%
3 Years-46.31%
TTM242.66%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM14.24%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM15.79%
Return on Capital
10 Years-2.43%
5 Years-4.32%
3 Years-19.19%
Last Year-16.85%
ABCL Recent Earnings
AbCellera Biologics Inc. (ABCL) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 9/12 qtrs (75%)●Beat Revenue 5/12 qtrs (42%)
Q2 2026Latest
May 11, 2026Metric
Actual
Est
EPS
$0.14+36.4%
$0.22
Rev
$8M+53.6%
$5M
Q1 2026
Feb 24, 2026Metric
Actual
Est
EPS
$0.03+83.3%
$0.18
Rev
$45M+572.9%
$7M
Q4 2025
Nov 6, 2025Metric
Actual
Est
EPS
$0.19-11.8%
$0.17
Rev
$9M+41.9%
$6M
Q3 2025
Aug 7, 2025Metric
Actual
Est
EPS
$0.12+29.4%
$0.17
Rev
$17M+168.6%
$6M
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 11, 2026 | $0.14vs $0.22+36.4% | $8Mvs $5M+53.6% |
| Q1 2026 | Feb 24, 2026 | $0.03vs $0.18+83.3% | $45Mvs $7M+572.9% |
| Q4 2025 | Nov 6, 2025 | $0.19vs $0.17-11.8% | $9Mvs $6M+41.9% |
| Q3 2025 | Aug 7, 2025 | $0.12vs $0.17+29.4% | $17Mvs $6M+168.6% |
Based on last 12 quarters of dataView full earnings history →
ABCL Peer Comparison
AbCellera Biologics Inc. (ABCL) competitors in Drug Discovery and Antibody Platforms — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 TWST | 5.45B | 87.56 | -67.35 | 20.32% | -19.85% | -17.46% | 0.29 | |
 RXRX | 1.44B | 3.23 | -2.24 | 26.92% | -8.44% | -54.32% | 0.07 | |
 SDGR | 1.18B | 15.76 | -11.18 | 23.29% | -40.6% | -30.85% | 0.30 | |
 BEAM | 3.51B | 34.14 | -42.15 | 120.01% | -49.17% | -5.89% | 0.24 | |
 SEER | 95.67M | 1.74 | -1.36 | 15.57% | -468.74% | -26.58% | 0.09 | |
 REGN | 63.37B | 609.94 | 14.70 | 0.99% | 29.65% | 14.32% | 0.09 | |
 HALO | 8.13B | 68.55 | 26.78 | 37.55% | 23.13% | 126.27% | 43.89 | |
 XNCR | 927M | 12.64 | -10.19 | 13.65% | -185.71% | -28.77% | 0.30 |
Compare ABCL vs Peers
AbCellera Biologics Inc. (ABCL) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
ABCL Income Statement
AbCellera Biologics Inc. (ABCL) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Metric | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|
Sales/Revenue | 8.83M | 11.61M | 233.16M | 375.2M | 485.42M | 38.02M | 28.83M | 75.13M | 79.21M |
Revenue Growth % | - | 31.49% | 1907.88% | 60.92% | 29.38% | -92.17% | -24.17% | 160.56% | 242.66% |
Cost of Goods Sold | 0 | 0 | 27.14M | 45.52M | 66.44M | 0 | 0 | 28.82M | 16.57M |
COGS % of Revenue | - | - | 11.64% | 12.13% | 13.69% | - | - | 38.36% | - |
Gross Profit | 8.83M▲ 0% | 11.61M▲ 31.5% | 206.01M▲ 1674.1% | 329.69M▲ 60.0% | 418.99M▲ 27.1% | 38.02M▼ 90.9% | 28.83M▼ 24.2% | 46.31M▲ 60.6% | 62.63M▲ 0% |
Gross Margin % | 100% | 100% | 88.36% | 87.87% | 86.31% | 100% | 100% | 61.64% | 79.07% |
Gross Profit Growth % | - | 31.49% | 1674.13% | 60.03% | 27.09% | -90.92% | -24.17% | 60.6% | - |
Operating Expenses | 9.58M | 15.73M | 49.98M | 125.27M | 202.48M | 275.23M | 343.6M | 263.41M | 274.6M |
OpEx % of Revenue | 108.53% | 135.45% | 21.44% | 33.39% | 41.71% | 723.82% | 1191.69% | 350.62% | - |
Selling, General & Admin | 2.86M | 4.01M | 15.75M | 48.76M | 66.75M | 75.18M | 85.49M | 76.58M | 72.88M |
SG&A % of Revenue | 32.42% | 34.55% | 6.76% | 13% | 13.75% | 197.71% | 296.5% | 101.93% | - |
Research & Development | 5.8M | 10.11M | 29.39M | 62.06M | 107.88M | 175.66M | 167.26M | 186.83M | 191M |
R&D % of Revenue | 65.71% | 87.09% | 12.61% | 16.54% | 22.22% | 461.95% | 580.1% | 248.68% | - |
Other Operating Expenses | 918K | 1.6M | 4.84M | 14.45M | 27.84M | 24.39M | 90.85M | 0 | 2M |
Operating Income | -753K▲ 0% | -4.12M▼ 446.7% | 156.03M▲ 3889.9% | 204.41M▲ 31.0% | 216.51M▲ 5.9% | -237.21M▼ 209.6% | -314.77M▼ 32.7% | -217.1M▲ 31.0% | -211.96M▲ 0% |
Operating Margin % | -8.53% | -35.45% | 66.92% | 54.48% | 44.6% | -623.82% | -1091.69% | -288.98% | -267.61% |
Operating Income Growth % | - | -446.75% | 3889.92% | 31.01% | 5.92% | -209.56% | -32.7% | 31.03% | - |
EBITDA | 165K | -2.27M | 161.3M | 221.66M | 249.61M | -206.31M | -217.77M | -188.28M | -181.09M |
EBITDA Margin % | 1.87% | -19.55% | 69.18% | 59.08% | 51.42% | -542.57% | -755.27% | -250.61% | -228.63% |
EBITDA Growth % | - | -1475.76% | 7205.81% | 37.42% | 12.61% | -182.65% | -5.55% | 13.54% | 19.76% |
D&A (Non-Cash Add-back) | 918K | 1.85M | 5.27M | 17.25M | 33.1M | 30.89M | 97M | 28.82M | 30.87M |
EBIT | 521K | -2M | 164.34M | 221.9M | 227.06M | -223.05M | -301.15M | -217.1M | -205.54M |
Net Interest Income | -170K | -54K | -6.22M | -1.9M | 12.03M | 42.25M | 38.47M | 28.33M | 23.92M |
Interest Income | 42K | 155K | 293K | 3.33M | 16.08M | 42.25M | 38.47M | 28.33M | 23.92M |
Interest Expense | 212K | 209K | 6.51M | 5.22M | 4.04M | 0 | 0 | 0 | 0 |
Other Income/Expense | 1.06M | 1.91M | 1.8M | 14.74M | 22.59M | 63.18M | 114.37M | 39.51M | 37.82M |
Pretax Income | 309K▲ 0% | -2.21M▼ 815.5% | 157.83M▲ 7238.5% | 219.15M▲ 38.8% | 239.1M▲ 9.1% | -174.03M▼ 172.8% | -200.4M▼ 15.2% | -177.59M▲ 11.4% | -174.15M▲ 0% |
Pretax Margin % | 3.5% | -19.04% | 67.69% | 58.41% | 49.26% | -457.67% | -695.02% | -236.39% | -219.86% |
Income Tax | 0 | 0 | 38.91M | 65.69M | 80.58M | -27.63M | -37.54M | -31.18M | -30.19M |
Effective Tax Rate % | 0% | 0% | 24.66% | 29.97% | 33.7% | 15.88% | 18.73% | 17.56% | 17.34% |
Net Income | 309K▲ 0% | -2.21M▼ 815.5% | 118.92M▲ 5478.5% | 153.46M▲ 29.1% | 158.52M▲ 3.3% | -146.4M▼ 192.4% | -162.86M▼ 11.2% | -146.41M▲ 10.1% | -143.96M▲ 0% |
Net Margin % | 3.5% | -19.04% | 51% | 40.9% | 32.66% | -385% | -564.83% | -194.88% | -181.75% |
Net Income Growth % | - | -815.53% | 5478.47% | 29.05% | 3.29% | -192.35% | -11.24% | 10.1% | 14.24% |
Net Income (Continuing) | 309K | -2.21M | 118.92M | 153.46M | 158.52M | -146.4M | -162.86M | -146.41M | -143.96M |
Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
EPS (Diluted) | 0.00▲ 0% | -0.01▼ 615.0% | 0.45▲ 4468.9% | 0.48▲ 6.7% | 0.50▲ 4.2% | -0.51▼ 202.0% | -0.55▼ 7.8% | -0.49▲ 10.9% | -0.48▲ 0% |
EPS Growth % | - | - | 4468.93% | 6.67% | 4.17% | -202% | -7.84% | 10.91% | 15.79% |
EPS (Basic) | 0.00 | -0.01 | 0.32 | 0.56 | 0.56 | -0.51 | -0.55 | -0.49 | - |
Diluted Shares Outstanding | 151.04M | 237.72M | 263.13M | 318.29M | 314.83M | 289.17M | 294.33M | 298.71M | 303.07M |
Basic Shares Outstanding | 151.06M | 215.41M | 267.82M | 275.76M | 285.06M | 289.17M | 294.33M | 298.71M | 303.07M |
Dividend Payout Ratio | - | - | - | - | - | - | - | - | - |
ABCL Balance Sheet
AbCellera Biologics Inc. (ABCL) balance sheet — assets, liabilities & shareholders' equity
| Metric | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|
Total Current Assets | 15.16M | 12.64M | 813.33M | 929.8M | 1.03B | 871.99M | 751.37M | 728.23M | 664.6M |
Cash & Short-Term Investments | 10.44M | 7.55M | 594.12M | 722.98M | 886.49M | 760.59M | 625.61M | 560.33M | 504.73M |
Cash Only | 10.44M | 7.55M | 594.12M | 476.14M | 386.54M | 133.32M | 156.32M | 155.01M | 77.06M |
Short-Term Investments | 0 | 0 | 0 | 246.84M | 499.95M | 627.26M | 469.29M | 405.31M | 427.67M |
Accounts Receivable | 1.4M | 2.12M | 213.73M | 160.58M | 38.59M | 64.38M | 92.13M | 153.4M | 115.72M |
Days Sales Outstanding | 58.05 | 66.76 | 334.59 | 156.21 | 29.02 | 618 | 1.17K | 745.27 | 670.32 |
Inventory | 0 | 163K | 1.41M | 1.67M | 1.53M | 1.11M | 0 | 6.34M | 0 |
Days Inventory Outstanding | - | - | 18.93 | 13.41 | 8.42 | - | - | 80.24 | 34.88 |
Other Current Assets | 2.76M | 2.25M | 0 | 39.28M | 89.82M | 45.91M | 33.63M | 8.17M | 44.14M |
Total Non-Current Assets | 6.33M | 10.85M | 192.21M | 388.77M | 515.42M | 616.11M | 609.18M | 628.72M | 642.52M |
Property, Plant & Equipment | 6.33M | 8.48M | 17.92M | 111.62M | 217.25M | 287.7M | 340.43M | 428M | 422.81M |
Fixed Asset Turnover | 1.40x | 1.37x | 13.01x | 3.36x | 2.23x | 0.13x | 0.08x | 0.18x | 0.19x |
Goodwill | 0 | 0 | 31.5M | 47.81M | 47.81M | 47.81M | 47.81M | 47.81M | 47.81M |
Intangible Assets | 0 | 0 | 115.15M | 148.39M | 131.5M | 120.42M | 42.11M | 38.38M | 37.46M |
Long-Term Investments | 0 | 0 | 20.03M | 50.31M | 72.52M | 65.94M | 82.3M | 62.58M | 311.56M |
Other Non-Current Assets | 0 | 2.37M | 1.71M | 23.23M | 41.03M | 94.24M | 96.54M | 51.95M | 69.14M |
Total Assets | 21.49M▲ 0% | 23.49M▲ 9.3% | 1.01B▲ 4181.1% | 1.32B▲ 31.1% | 1.54B▲ 16.9% | 1.49B▼ 3.4% | 1.36B▼ 8.6% | 1.36B▼ 0.3% | 1.31B▲ 0% |
Asset Turnover | 0.41x | 0.49x | 0.23x | 0.28x | 0.32x | 0.03x | 0.02x | 0.06x | 0.06x |
Asset Growth % | - | 9.29% | 4181.06% | 31.13% | 16.86% | -3.43% | -8.57% | -0.26% | -6.41% |
Total Current Liabilities | 6.43M | 7.89M | 103.49M | 120.68M | 118.32M | 119.01M | 76.61M | 64.31M | 47.29M |
Accounts Payable | 1.52M | 1.64M | 7.32M | 14.92M | 14.83M | 25.51M | 34.35M | 25.23M | 20.81M |
Days Payables Outstanding | - | - | 98.43 | 119.68 | 81.47 | - | - | 319.5 | 604.76 |
Short-Term Debt | 2.53M | 2.47M | 190K | 0 | 0 | 0 | 0 | 5.82M | 5.87M |
Deferred Revenue (Current) | 2.33M | 0 | 7.53M | 7.54M | 21.61M | 18.96M | 21.18M | 13.53M | 71.02M |
Other Current Liabilities | 50.12K | 3.37M | 9.08M | 54.85M | 69.84M | 60.68M | 8.09M | 8.98M | 12.87M |
Current Ratio | 2.36x | 1.60x | 7.86x | 7.70x | 8.67x | 7.33x | 9.81x | 11.32x | 14.05x |
Quick Ratio | 2.36x | 1.58x | 7.85x | 7.69x | 8.65x | 7.32x | 9.81x | 11.23x | 14.05x |
Cash Conversion Cycle | - | - | 255.09 | 49.94 | -44.03 | - | - | 506.02 | 100.44 |
Total Non-Current Liabilities | 3.45M | 5.34M | 71.54M | 172.16M | 189.31M | 216.76M | 227.86M | 151.29M | 145.63M |
Long-Term Debt | 911.22K | 1.36M | 2.2M | 0 | 0 | 0 | 0 | 0 | 0 |
Capital Lease Obligations | 0 | 2.64M | 3.71M | 36.41M | 76.67M | 71.22M | 60.74M | 137.4M | 545.95M |
Deferred Tax Liabilities | 0 | 0 | 26.16M | 37.37M | 33.18M | 30.61M | 10.05M | 9.12M | 28.91M |
Other Non-Current Liabilities | 277.13K | 1.34M | 13.57M | 37.62M | 19.14M | 10.82M | 1.47M | 4.77M | 11.32M |
Total Liabilities | 9.88M | 13.24M | 175.03M | 292.84M | 307.63M | 335.78M | 304.47M | 215.59M | 192.92M |
Total Debt | 3.44M | 6.89M | 6.78M | 40.06M | 82.26M | 77.38M | 65.36M | 143.22M | 140.18M |
Net Debt | -7M | -662K | -587.34M | -436.08M | -304.28M | -55.94M | -90.96M | -11.79M | 63.12M |
Debt / Equity | 0.30x | 0.67x | 0.01x | 0.04x | 0.07x | 0.07x | 0.06x | 0.13x | 0.15x |
Debt / EBITDA | 20.86x | - | 0.04x | 0.18x | 0.33x | - | - | - | -0.77x |
Net Debt / EBITDA | -42.43x | - | -3.64x | -1.97x | -1.22x | - | - | - | -0.35x |
Interest Coverage | 2.46x | -9.58x | 25.24x | 42.47x | 56.13x | - | - | - | - |
Total Equity | 11.61M▲ 0% | 10.25M▼ 11.7% | 830.51M▲ 8000.9% | 1.03B▲ 23.5% | 1.23B▲ 20.2% | 1.15B▼ 6.6% | 1.06B▼ 8.4% | 1.14B▲ 8.1% | 938.08M▲ 0% |
Equity Growth % | - | -11.69% | 8000.94% | 23.51% | 20.23% | -6.56% | -8.35% | 8.07% | -20.16% |
Book Value per Share | 0.08 | 0.04 | 3.16 | 3.22 | 3.92 | 3.98 | 3.59 | 3.82 | 3.10 |
Total Shareholders' Equity | 11.61M | 10.25M | 830.51M | 1.03B | 1.23B | 1.15B | 1.06B | 1.14B | 938.08M |
Common Stock | 5.07M | 5.12M | 710.39M | 722.43M | 734.37M | 753.2M | 777.17M | 802.34M | 816.53M |
Retained Earnings | -2.5M | -4.72M | 114.2M | 267.67M | 426.19M | 279.79M | 116.93M | -29.48M | -72.65M |
Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accumulated OCI | 0 | 0 | 0 | 280K | -1.39M | -1.72M | -4.38M | -4.23M | -2.42M |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
ABCL Cash Flow Statement
AbCellera Biologics Inc. (ABCL) cash flow — operating, investing & free cash flow history
| Metric | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|
Cash from Operations | 3.56M | 2.69M | 22.69M | 244.58M | 277.36M | -43.88M | -108.56M | -131.29M | -153.26M |
Operating CF Margin % | 40.37% | 23.2% | 9.73% | 65.19% | 57.14% | -115.39% | -376.5% | -174.76% | - |
Operating CF Growth % | - | -24.43% | 742.24% | 977.94% | 13.4% | -115.82% | -147.41% | -20.95% | -615.8% |
Net Income | 309K | -2.21M | 118.92M | 153.46M | 158.52M | -146.4M | -162.86M | -146.41M | -143.96M |
Depreciation & Amortization | 918K | 1.85M | 5.27M | 17.25M | 33.1M | 30.89M | 97M | 22.17M | 31.94M |
Stock-Based Compensation | 615K | 890K | 8.4M | 30.65M | 49.48M | 64.18M | 67.58M | 55.79M | 41.01M |
Deferred Taxes | 0 | 0 | 2.1M | -2.02M | -2.11M | 1.96M | 0 | 0 | 0 |
Other Non-Cash Items | -188K | 194K | 4.71M | 3.57M | 8.55M | -7.74M | -84.44M | 7.85M | 12.08M |
Working Capital Changes | 1.91M | 1.97M | -116.7M | 41.67M | 29.82M | 13.22M | -25.84M | -70.69M | -94.33M |
Change in Receivables | -477K | -1.8M | -203.02M | 22.48M | -22.71M | -45.93M | -75.12M | -55.62M | -41.26M |
Change in Inventory | -897.77K | 0 | 0 | 0 | 0 | 18.25M | 0 | 0 | 0 |
Change in Payables | 180K | 150K | 6.6M | 1.4M | 1.07M | -15.1M | 10.63M | 3.46M | -2.5M |
Cash from Investing | -5.31M | -5.78M | -119.78M | -332.25M | -352.63M | -221.11M | 121.41M | 87.75M | 54.73M |
Capital Expenditures | -5.31M | -4M | -9.67M | -58.45M | -72.66M | -77.51M | -78.4M | -42.77M | -35.97M |
CapEx % of Revenue | 60.1% | 34.42% | 4.15% | 15.58% | 14.97% | 203.83% | 271.9% | 56.93% | 45.41% |
Acquisitions | 0 | 0 | -106.89M | -11.46M | -25.68M | -13.69M | -19.63M | 0 | -7.55M |
Investments | - | - | - | - | - | - | - | - | - |
Other Investing | 0 | -1.78M | -3.22M | 32.62M | 16.43M | 25.31M | 35.71M | 566.57M | 101.35M |
Cash from Financing | 12.19M | 195K | 683.65M | -3.89M | -1.63M | 10.36M | 12.77M | 14.08M | 15.3M |
Debt Issued (Net) | 1.98M | 181K | 85.15M | -951K | 2.75M | 11.59M | 13.5M | 0 | 5.5M |
Equity Issued (Net) | 10.17M | 14.16K | 597.5M | 4.62M | 0 | 0 | 0 | 0 | 0 |
Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Financing | 37K | 25K | 1M | -7.55M | -4.38M | -1.23M | -729K | 14.08M | 9.8M |
Net Change in Cash | 10.44M▲ 0% | -2.89M▼ 127.7% | 586.56M▲ 20389.3% | -92.97M▼ 115.9% | -86.49M▲ 7.0% | -254.04M▼ 193.7% | 23M▲ 109.1% | -28.37M▼ 223.3% | -84.26M▲ 0% |
Free Cash Flow | -1.74M▲ 0% | -1.3M▲ 25.2% | 8.02M▲ 715.3% | 186.13M▲ 2221.7% | 204.7M▲ 10.0% | -121.38M▼ 159.3% | -186.95M▼ 54.0% | -174.07M▲ 6.9% | -189.23M▲ 0% |
FCF Margin % | -19.73% | -11.22% | 3.44% | 49.61% | 42.17% | -319.22% | -648.4% | -231.69% | -238.91% |
FCF Growth % | - | 25.2% | 715.27% | 2221.72% | 9.98% | -159.3% | -54.02% | 6.89% | -32.65% |
FCF per Share | -0.01 | -0.01 | 0.03 | 0.58 | 0.65 | -0.42 | -0.64 | -0.58 | -0.62 |
FCF Conversion (FCF/Net Income) | 11.54x | -1.22x | 0.19x | 1.59x | 1.75x | 0.30x | 0.67x | 0.90x | 1.31x |
Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
ABCL Key Ratios
AbCellera Biologics Inc. (ABCL) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|
Return on Equity (ROE) | -20.23% | 28.29% | 16.53% | 14.03% | -12.27% | -14.75% | -13.33% | -14.22% |
Return on Invested Capital (ROIC) | -43.5% | 92.6% | 36.82% | 21.39% | -17.57% | -22.9% | -15.55% | -15.1% |
Gross Margin | 100% | 88.36% | 87.87% | 86.31% | 100% | 100% | 61.64% | 79.07% |
Net Margin | -19.04% | 51% | 40.9% | 32.66% | -385% | -564.83% | -194.88% | -181.75% |
Debt / Equity | 0.67x | 0.01x | 0.04x | 0.07x | 0.07x | 0.06x | 0.13x | 0.15x |
Interest Coverage | -9.58x | 25.24x | 42.47x | 56.13x | - | - | - | - |
FCF Conversion | -1.22x | 0.19x | 1.59x | 1.75x | 0.30x | 0.67x | 0.90x | 1.31x |
Revenue Growth | 31.49% | 1907.88% | 60.92% | 29.38% | -92.17% | -24.17% | 160.56% | 242.66% |
Related:ABCL Dividend History·ABCL Revenue History·ABCL Price History·ABCL P/E History·ABCL Financial Ratios·ABCL Institutional Holders
ABCL SEC Filings & Documents
AbCellera Biologics Inc. (ABCL) SEC filings — annual & quarterly reports (10-K, 10-Q)
ABCL Frequently Asked Questions
AbCellera Biologics Inc. (ABCL) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
AbCellera Biologics Inc. (ABCL) reported $79.2M in revenue for fiscal year 2025. This represents a 797% increase from $8.8M in 2018.
AbCellera Biologics Inc. (ABCL) grew revenue by 160.6% over the past year. This is strong growth.
AbCellera Biologics Inc. (ABCL) reported a net loss of $144.0M for fiscal year 2025.
Dividend & Returns
AbCellera Biologics Inc. (ABCL) has a return on equity (ROE) of -13.3%. Negative ROE indicates the company is unprofitable.
AbCellera Biologics Inc. (ABCL) had negative free cash flow of $189.2M in fiscal year 2025, likely due to heavy capital investments.